MedTrace Logo

National Danish Protocol. Surgery+ SBRT for M1 Prostate Cancer Patients

NCT04086290 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2020-02-12

No results posted yet for this study

Summary

A prospective, open label phase 2 clinical trial assessing safety, complications and feasibility of radical prostatectomy (RARP) plus local stereotactic body radiotherapy (SBRT) to bone metastases in combination with short-term medical castration to a select population of prostate cancer patients with oligometastatic disease.

Conditions

  • Prostate Cancer Metastatic

Interventions

PROCEDURE

RARP

Radical prostatectomy + extended pelvic lymph node dissection

RADIATION

SBRT

Stereotactic body radiotherapy to osseous lesions

DRUG

ADT

six month of neo-adjuvant/concomitant medical castration therapy using a gonadotropin-releasing hormone antagonist or agonist.

Sponsors & Collaborators

  • Peter Busch Østergren

    lead OTHER

Principal Investigators

  • Peter B Østergren, MD · Herlev and Gentofte Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-10
Primary Completion
2023-10-31
Completion
2028-10-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04086290 on ClinicalTrials.gov